tiprankstipranks
Trending News
More News >

Bvf Partners LP Il Insider Profile

438 Followers
Bvf Partners LP Il, See Explanation of Responses at ChemoCentryx, holds 560.80K shares in ESSA Pharma (Ticker: EPIX), holds 353.41K shares in Kymera Therapeutics (Ticker: KYMR), holds 62.38K shares in Crescent Biopharma (Ticker: CBIO).
tipranks
Bvf Partners LP Il

Bvf Partners LP Il
ChemoCentryx (CCXI)
See Explanation of Responses

Ranked #38 out of 103,104 Corporate Insiders

Profitable Transactions

63%
90 out of 144 Profitable Transactions

Average Return

+50.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$5B
28.71%
25.75%
22.77%
6.72%
16.06% Others
A breakdown of Bvf Partners LP Il's holdings

Insider Roles

Repligen
(RGEN)
Indirect Beneficial Owner, Ten Percent Owner
Neurocrine
(NBIX)
See Explanation of Responses
MoonLake Immunotherapeutics
(MLTX)
Director, Ten Percent Owner
Rigel
(RIGL)
Ten Percent Owner
+24 other positions
Roles that Bvf Partners LP Il holds in companies

Most Profitable Insider Trade

Stock:
Five Prime Therapeutics
(FPRX)
Rating:Informative Buy
Date:Nov 26, 2019 - Nov 26, 2020
Return:+467.90%
The most profitable trade made by Bvf Partners LP Il

Bvf Partners LP Il's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
CCXI
ChemoCentryx
Nov 05, 2015
Uninformative Sell
$177.51M
CTIC
CTI BioPharma
Jun 28, 2023
Uninformative Sell
80.59M
$0.00
Xenon
Mar 29, 2018
Ten Percent Owner
Uninformative Sell
$2.24M
Infinity Pharmaceuticals
Feb 16, 2021
See Explanation of Responses
Informative Sell
12.11M
Xoma
May 20, 2025
Ten Percent Owner
Informative Sell
10.64M
$41.14M
Crescent Biopharma
Jun 17, 2025
Ten Percent Owner
Uninformative Buy
$860.89K
CNCE
Concert Pharma
Jun 12, 2019
Informative Sell
4.13M
$1.42M
Syndax Pharmaceuticals
Jun 20, 2018
Ten Percent Owner
Uninformative Sell
$1.34M
IMDZ
Immune Design
Dec 04, 2018
Informative Sell
1.65M
$2.17M
Palvella Therapeutics
Dec 17, 2024
See Explanation of Responses
Uninformative Buy
$1.97M
FPRX
Five Prime Therapeutics
Nov 13, 2020
Informative Sell
149.20M
$3.09M
CALA
Calithera Bio
May 26, 2020
Informative Sell
13.70M
$12.01K
Cytokinetics
Feb 18, 2020
See Explanaton of Responses
Informative Sell
16.92M
$263.70M
Merus
Oct 08, 2021
Ten Percent Owner
Informative Sell
31.22M
$15.00M
IDEAYA Biosciences
Feb 04, 2021
See Explanation of Responses
Informative Sell
835.36K
$5.67M
PRNB
Principia Biopharma
Kymera Therapeutics
Jul 01, 2025
Director, See Remarks and Footnotes
Informative Buy
13.96M
$14.97M
Olema Pharmaceuticals
Jan 14, 2025
Director, See Explanation of Responses
Uninformative Sell
$27.84M
Eledon Pharmaceuticals
May 13, 2024
Ten Percent Owner
Uninformative Buy
$16.04M
CytomX Therapeutics
See Explanation of Responses
$10.77M
RAIN
Rain Oncology
Jan 29, 2024
Uninformative Sell
$0.00
Repare Therapeutics
Nov 17, 2023
Ten Percent Owner
Informative Buy
6.24M
$842.62K
Cullinan Management
Jan 19, 2023
Ten Percent Owner
Uninformative Sell
$479.28K
THRD
Third Harmonic Bio, Inc.
Oct 31, 2024
Informative Sell
14.30M
$950.60K
Structure Therapeutics, Inc. Sponsored ADR
May 12, 2023
Ten Percent Owner
Uninformative Sell
$96.05M
MoonLake Immunotherapeutics
Oct 08, 2024
Director, Ten Percent Owner
Informative Sell
100.00M
$1.07B
PNT
POINT Biopharma Global
Dec 20, 2023
Informative Sell
213.66M
$0.00
4D Molecular Therapeutics
Nov 13, 2024
See Explanation of Responses
Uninformative Sell
$602.19K
ALLK
Allakos
May 19, 2025
Uninformative Sell
$0.00
ESSA Pharma
Aug 07, 2025
Ten Percent Owner
Uninformative Buy
291.72
$1.08M
Gyre Therapeutics
Nov 19, 2012
See Explanation of Responses
Informative Buy
5.24M
$18.59M
CASC
Cascadian Therapeutics
Dec 22, 2015
Informative Buy
$207.39M
Dynavax
Sep 11, 2009
Ten Percent Owner
Informative Sell
3.35M
$178.34M
Neurocrine
Oct 14, 2011
See Explanation of Responses
Informative Buy
175.53K
$1.21B
Repligen
Jul 08, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
5.50K
$1.34B
EPRSQ
Epirus Biopharma
Dec 24, 2009
Informative Sell
2.54M
$13.66M
~ARRY
Array Biopharma
Jul 10, 2014
Uninformative Sell
2.25M
$596.76M
AMAG
Amag Pharmaceuticals
$14.15M
ARQL
Arqule
Jun 01, 2018
Informative Sell
5.18M
$15.43M
Rigel
Nov 20, 2013
Ten Percent Owner
Informative Sell
1.28M
$314.70M
TBRA
Tobira Therapeutics
Mar 25, 2014
Uninformative Sell
$47.19M
Curis
Apr 29, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
3.42M
$9.23M
~RPRX
Repros
$1.12M
Ligand Pharma
Mar 26, 2014
See Explanation of Responses
Informative Sell
5.48M
$20.21M
Palatin Technologies
Mar 03, 2014
Ten Percent Owner
Informative Sell
320.27K
$24.95M
~ASTX
Astex Pharmaceuticals
Medicinova
Ten Percent Owner
$0.00
NPSP
NPS Pharma
List of latest transactions for each holding click on a transaction to see Bvf Partners LP Il's performance on stock

Bvf Partners LP Il insider profile FAQ

What is the percentage of profitable transactions made by Bvf Partners LP Il?
The percentage of profitable transactions made by Bvf Partners LP Il is 63%.
    What is the average return per transaction made by Bvf Partners LP Il?
    The average return per transaction made by Bvf Partners LP Il is 50.50%.
      What stocks does Bvf Partners LP Il hold?
      Bvf Partners LP Il holds: CCXI, CTIC, XENE, INFIQ, XOMA, CBIO, CNCE, SNDX, IMDZ, PVLA, FPRX, CALA, CYTK, MRUS, IDYA, PRNB, KYMR, OLMA, ELDN, CTMX, RAIN, RPTX, CGEM, THRD, GPCR, MLTX, PNT, FDMT, ALLK, EPIX, GYRE, CASC, DVAX, NBIX, RGEN, EPRSQ, ~ARRY, AMAG, ARQL, RIGL, TBRA, CRIS, ~RPRX, LGND, PTNTD, ~ASTX, MNOV, NPSP stocks.
        What was Bvf Partners LP Il’s latest transaction?
        Bvf Partners LP Il latest transaction was an Uninformative Buy of $291.72.
          What was Bvf Partners LP Il's most profitable transaction?
          Bvf Partners LP Il’s most profitable transaction was an Informative Buy of FPRX stock on November 26, 2019. The return on the trade was 467.90%.
            What is Bvf Partners LP Il's role in ChemoCentryx?
            Bvf Partners LP Il's role in ChemoCentryx is See Explanation of Responses.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.